PDF(Pubmed)
Abstract：
UNASSIGNED: In recent years, new hypoglycaemic drugs that affect the incretin system have become increasingly popular in the treatment of type 2 diabetes mellitus (T2DM): glucagon-like receptor 1 agonists (GLP1RAs), dipeptidyl peptidase 4 inhibitors (DPP4is) and the recently developed dual glucagon-like receptor 1 agonist and glucose-dependent insulinotropic polypeptide (tirzepatide). Their main role of these drugs is to normalise blood glucose levels. In addition, GLP1RAs are approved for the treatment of excessive body weight. The efficacy of drugs affecting the incretin system is well described in the literature, however, there are still only few reports about their safety. This review aims to summarize the results of current research and meta-analyses on risk of acute pancreatitis (AP) during incretin-affecting drugs treatment.
UNASSIGNED: A narrative review was performed using present literature in an attempt to identify the relationship between AP and incretin-affecting drugs. The following keywords were used: acute pancreatitis, glucagon-like receptor 1 agonists, dipeptidyl peptidase 4 inhibitors and tirzepatide.
UNASSIGNED: It was demonstrated that the use of DPP4is is safe for the majority of patients with T2DM, whereas a risk of AP should be noted in case of GLP1RAs therapy. To date, most studies found no significant association between tirzepatide therapy and the increased risk of AP.
UNASSIGNED: The majority of studies have shown that DPP4is, GLP1RAs and tirzepatide are effective and safe in most T2DM patients. However, the follow-up time for patients treated with tirzepatide is short, therefore more studies are required to confirm the safety of this drug.
UNASSIGNED: A narrative review was performed using present literature in an attempt to identify the relationship between AP and incretin-affecting drugs. The following keywords were used: acute pancreatitis, glucagon-like receptor 1 agonists, dipeptidyl peptidase 4 inhibitors and tirzepatide.
UNASSIGNED: It was demonstrated that the use of DPP4is is safe for the majority of patients with T2DM, whereas a risk of AP should be noted in case of GLP1RAs therapy. To date, most studies found no significant association between tirzepatide therapy and the increased risk of AP.
UNASSIGNED: The majority of studies have shown that DPP4is, GLP1RAs and tirzepatide are effective and safe in most T2DM patients. However, the follow-up time for patients treated with tirzepatide is short, therefore more studies are required to confirm the safety of this drug.
摘要：
■近年来，影响肠促胰岛素系统的新降血糖药物在2型糖尿病（T2DM）的治疗中越来越受欢迎：胰高血糖素样受体1激动剂（GLP1RAs），二肽基肽酶4抑制剂（DPP4is）和最近开发的双重胰高血糖素样受体1激动剂和葡萄糖依赖性促胰岛素多肽（tirzepatide）。这些药物的主要作用是使血糖水平正常化。此外,GLP1RA被批准用于治疗体重过重。影响肠促胰岛素系统的药物的功效在文献中有很好的描述，然而,关于他们安全的报道仍然很少。这篇综述旨在总结当前关于肠促胰岛素影响药物治疗期间急性胰腺炎（AP）风险的研究和荟萃分析的结果。
■使用现有文献进行叙述性综述，试图确定AP与影响肠促胰岛素的药物之间的关系。使用以下关键词：急性胰腺炎，胰高血糖素样受体1激动剂，二肽基肽酶4抑制剂和替西平肽。
■已证明使用DPP4is对大多数T2DM患者是安全的，而在GLP1RAs治疗的情况下，应注意AP的风险。迄今为止,大多数研究发现,替瑞哌肽治疗与AP风险增加之间没有显著关联.
■大多数研究表明DPP4是，GLP1RAs和替利西帕肽在大多数T2DM患者中是有效和安全的。然而,替瑞哌肽治疗的患者随访时间短，因此需要更多的研究来证实这种药物的安全性。
■使用现有文献进行叙述性综述，试图确定AP与影响肠促胰岛素的药物之间的关系。使用以下关键词：急性胰腺炎，胰高血糖素样受体1激动剂，二肽基肽酶4抑制剂和替西平肽。
■已证明使用DPP4is对大多数T2DM患者是安全的，而在GLP1RAs治疗的情况下，应注意AP的风险。迄今为止,大多数研究发现,替瑞哌肽治疗与AP风险增加之间没有显著关联.
■大多数研究表明DPP4是，GLP1RAs和替利西帕肽在大多数T2DM患者中是有效和安全的。然而,替瑞哌肽治疗的患者随访时间短，因此需要更多的研究来证实这种药物的安全性。
